At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 158 enrolled
Drug / intervention
Collagenase Clostridium Histolyticumbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
In Brief
A Phase 2 clinical trial evaluating Collagenase Clostridium Histolyticum for Edematous Fibrosclerotic Panniculopathy and Cellulite. Completed, enrolled 158 participants across 11 sites.
Detailed Summary
An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEdematous Fibrosclerotic Panniculopathy, Cellulite
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 17, 2017
Primary CompletionSep 5, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.7 years ago
Interventions
Collagenase Clostridium Histolyticumbiological
During 3 treatment visits 12 injections will be given per treatment area